Skip to main content

Table 1 Studies That Assessed Impact of PSMA PET/CT on SRT Planning

From: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]

Author

Year

n

PSA (ng/ml) Median (range)

PSMA+

Extrapelvic PSMA+

Any SRT Planning Change

SRT Considered Futile

Shakespeare

2015

18

1.1 (0.017–20.4)

NA

NA

46%

NA

van Leeuwen

2015

70

0.2 (0.05–0.99)

55%

6%

35%

7%

Sterzing

2016

42

2.8 (0.16–113)

60%

NA

61%

NA

Bluemel

2016

45

0.67 (0.10–11.2)

54%

9%

42%

4%

Albisinni

2016

48

2.2 (0.72–6.7)

NA

NA

76%

NA

Schiller

2017

31

0.71 (0.12–14.7)

100%

3%

87%

0%

Henkenberens

2017

39

1.2 (0.3–15.5)

85%

46%

59%

13%

Schmidt-Hegemann

2017

49

0.49 (0.15–6.24)

NA

4%

57%

NA

Habl

2017

83

0.69 (0.09–14.7)

71%

10%

57%

0%

De Bari

2018

12

0.51 (0.10–1.62)

NA

NA

17%

8%

Koerber

2018

71

1.2 (0.03–41.24)

NA

51%

54%

3%

Frenzel

2018

75

0.2 (0.02–653.2)

NA

NA

43%

NA

Farolfi

2018

119

0.32 (0.20–0.50)

35%

21%

30%

18%

Calais

2018

270

0.48 (0.03–1.0)

49%

13%

19%

12%